doi:10.19983/j.issn.2096-8493.20230011

Abstract

CLC Number:

Figures/Tables 2

References 16

[1]	Pop LG, Bacalbasa N, Suciu ID, et al. Tuberculosis in pregnancy. J Med Life, 2021, 14(2):165-169. doi:10.25122/jml-2021-0001. doi: 10.25122/jml-2021-0001 pmid: 34104238
[2]	Peng W, Yang J, Liu E. Analysis of 170 cases of congenital TB reported in the literature between 1946 and 2009. Pediatr Pulmonol, 2011, 46(12):1215-1224. doi:10.1002/ppul.21490. doi: 10.1002/ppul.21490 URL
[3]	夏世文, 彭斯聪. 新生儿先天性结核的诊断与治疗. 中华实用儿科临床杂志, 2020, 35(23):1766-1769. doi:10.3760/cma.j.cn101070-20201117-01768. doi: 10.3760/cma.j.cn101070-20201117-01768
[4]	邵肖梅, 叶鸿瑁, 丘小汕. 实用新生儿学. 5版. 北京: 人民卫生出版社, 2019:528-529.
[5]	Lei Q, Wang H, Zhao Y, et al. Determinants of serum concentration of first-line anti-tuberculosis drugs from China. Medicine (Baltimore), 2019, 98(41):e17523. doi:10.1097/MD.0000000000017523. doi: 10.1097/MD.0000000000017523 URL
[6]	Mittal H, Das S, Faridi MM. Management of newborn infant born to mother suffering from tuberculosis: current recommendations & gaps in knowledge. Indian J Med Res, 2014, 140(1):32-39. pmid: 25222775
[7]	Schaaf HS, Parkin DP, Seifart HI, et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child, 2005, 90(6):614-618. doi:10.1136/adc.2004.052175. doi: 10.1136/adc.2004.052175 pmid: 15908628
[8]	Zhu R, Kiser JJ, Seifart HI, et al. The pharmacogenetics of NAT 2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. J Clin Pharmacol, 2012, 52(4):511-519. doi:10.1177/0091270011402826. doi: 10.1177/0091270011402826 URL
[9]	Thee S, Seddon JA, Donald PR, et al. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. Antimicrob Agents Chemother, 2011, 55(12):5560-5567. doi:10.1128/AAC.05429-11. doi: 10.1128/AAC.05429-11 pmid: 21968358
[10]	Zuur MA, Bolhuis MS, Anthony R, et al. Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis. Expert Opin Drug Metab Toxicol, 2016, 12(5):509-521. doi:10.1517/17425255.2016.1162785. doi: 10.1517/17425255.2016.1162785 URL
[11]	World Health Organization. Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children. 2nd ed. Geneva: World Health Organization, 2014.
[12]	Bekker A, Schaaf HS, Draper HR, et al. Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines. Antimicrob Agents Chemother, 2016, 25;60(4):2171-2179. doi:10.1128/AAC.02600-15. doi: 10.1128/AAC.02600-15
[13]	Wang P, Pradhan K, Zhong XB, et al. Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B, 2016, 6(5):384-392. doi:10.1016/j.apsb.2016.07.014. doi: 10.1016/j.apsb.2016.07.014 pmid: 27709007
[14]	Thomas L, Raju AP, Chaithra, et al. Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models. Eur J Clin Pharmacol, 2022, 78(10):1535-1553. doi:10.1007/s00228-022-03362-7. doi: 10.1007/s00228-022-03362-7 pmid: 35852584
[15]	Zhu R, Kiser JJ, Seifart HI, et al. The pharmacogenetics of NAT 2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. J Clin Pharmacol, 2012, 52(4):511-519. doi:10.1177/0091270011402826. doi: 10.1177/0091270011402826 URL
[16]	McIlleron H, Willemse M, Werely CJ, et al. Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines. Clin Infect Dis, 2009, 48(11):1547-1553. doi:10.1086/598192. doi: 10.1086/598192 pmid: 19392636

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 16

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yang Shuqi, Li Feng. Advances in PD1/PD-L1 inhibitors in tuberculosis research [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 94-101.
[2]	Zhang Ying, Guo Chunhui. Research progress in the treatment of tuberculous tracheobronchial stenosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 87-93.
[3]	Yan Wenhua, Chen Wenjun. The value of digital health education in the preventive management of caregivers of patients with bacterial positive pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 73-78.
[4]	Gu Jinhua, Zhang Panpan. Evaluation of the application value of three detection methods for Mycobacterium tuberculosis in a comprehensive hospital [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 68-72.
[5]	Yan Qinghu, Xue Feng, Yu Yong, Qin Yi, Yan Qingmei, Cui Jia. The value of ultrasound-guided microwave ablation in the treatment of localized tuberculous lesions [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 55-60.
[6]	Qi Wei, Zhao Enyi. The epidemic characteristics and the trends of pulmonary tuberculosis in elderly and non-elderly in central urban area, Tianjin from 2006 to 2020 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 46-54.
[7]	Yang Yan, Dong Wen, Chen Jianjun, Zhang Yu. Epidemiologic characteristics of pulmonary tuberculosis in Zhuxi County, Shiyan City (2014-2023) [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 40-45.
[8]	Zheng Jianli, Wu Yumei, Zhang Shili, Du Zixian, Li Turong, Chen Shisheng, Lin Wenge. Cost-effectiveness analysis of active tuberculosis screening among high-risk populations in Longyan City, Fujian Province [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 35-39.
[9]	Zhao Yongnian, Zhang Lijie, Wang Tongmin. Analysis of the epidemiological characteristics of reported pulmonary tuberculosis in Xinjiang Production and Construction Corps, 2014—2023 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 30-34.
[10]	Wan Ying, Pang Xuewen, Zhang Fan. Evaluation on effect of health promotion for tuberculosis prevention and control in Tianjin City from 2010 to 2020 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 22-29.
[11]	Chen Yu, Li Xiaorui, Wang Miaoran, Zhang Yuqi, Liu Chang, Wang Zhaohua, Shi Jie, Fan Lichao, Yin Zhihua, Xie Jianping. The research progress on the role of metal ions in tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 102-112.
[12]	Chen Jing, Qin Yali, Wang Mingdong, Yang Rubin, Wang Qian, Peng Yanqing, Qiu Jiyao, Zhang Xiao, Zhou Xinai. The value of QuantiFERON-TB Gold Plus in the clinical diagnosis of active pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 61-67.
[13]	Liao Ying, Pang Yan, Zhao Jing, He Gaoqin, You Maolin, Wang Lei. Analysis on the reporting and case finding delay characteristics of pulmonary tuberculosis patients in Liangping District, Chongqing from 2018 to 2023 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 8-13.
[14]	. [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(6): 495-499.
[15]	Hu Xinyang, Gao Jingtao. Interpretation of WHO global tuberculosis report 2024 [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(6): 500-504.